Abstract
Summary
The global epigenetics market size is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period. Factors such as increased investments in research and development, coupled with a reduction in sequencing costs and time, support from government initiatives and funding for epigenetics research, advancements in technology for epigenetic research, and a growing interest in epigenetic-based therapeutics.
“The kits & reagents segment segment held the dominant share in the epigenetics market”
Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segment is anticipated to grow at significant CAGR. The rapid expansion of epigenetics studies, combined with the introduction of cost-effective and user-friendly kits by market participants are likely to have positive impact on the growth of the market.
“DNA methylation segment accounted for the largest share of the method segment in 2022.”
Based on method, the epigenetics market is segmented into, DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The segment held the dominant share in the market owing to the effectiveness of employing DNA methylation techniques for cancer research.
“Asia Pacific region is likely to grow at a faster pace in the epigenetics market.”
The epigenetics market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by enhancements in healthcare infrastructure within developing APAC economies, coupled with strategic partnerships, collaborations, agreements, and expansions pursued by local industry players.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 60%, and Demand Side - 40%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America: 40%, Europe: 27%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 3%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Abcam plc (UK)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories Inc. (US)
• Promega Corporation (US)
• Revvity (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Diagenode SA(US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• EpiGentek Group Inc. (US)
• EpiCypher (US)
• Fios Genomics (UK)
• GenomeScan (Netherlands)
• Creative Biogene (US)
• BPS Bioscienc Inc (US)
• Abnova Corporation (Taiwan)
• Creative Diagnostics (US)
• Biomodal (UK)
• Integrated DNA Technologies Inc. (US)
• Novogene Co Ltd (China)
Research Coverage:
This report provides a detailed picture of the epigenetics market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall epigenetics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (growing investment in research & development, declining sequencing cost & time, favorable government initiatives and funding for epigenetics research, technological advancements in epigenetic research and rising demand for epigenetic-based therapeutics), restraints (Limited application of epigenomic data in toxicology, data privacy concern and security issues associated with management of large scale- epigenetic data ), opportunities (Expanding application of epigenetics and integration of artificial intelligence and machine learning algorithm) and challenges (Concerns Regarding the Quality of Antibodies, Challenges associated epigenetics editing, off target effect) are influencing the growth of epigenetics market.
• Product Development/Innovation: Detailed insights on newly launched products of the epigenetics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the epigenetics market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the epigenetics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US) and Qiagen (Germany).
Table of Contents
1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.3 MARKET SCOPE 45
1.3.1 MARKETS COVERED 45
1.3.2 YEARS CONSIDERED 46
1.3.3 CURRENCY CONSIDERED 46
1.4 RESEARCH LIMITATIONS 46
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 47
1.7 RECESSION IMPACT 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 51
2.2 MARKET SIZE ESTIMATION 52
2.2.1 PRIMARY INSIGHTS 54
2.2.2 SEGMENTAL ASSESSMENT: EPIGENETICS MARKET 55
2.3 GROWTH RATE ASSUMPTIONS 56
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 58
2.5 STUDY ASSUMPTIONS 59
2.6 RISK ANALYSIS 59
2.7 RECESSION IMPACT: EPIGENETICS MARKET 59
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 65
4.1 EPIGENETICS MARKET OVERVIEW 65
4.2 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 66
4.3 EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 67
4.4 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
5.2.1 DRIVERS 69
- 5.2.1.1 Growing investments in research & development 69
- 5.2.1.2 Declining sequencing costs & time 70
- 5.2.1.3 Favorable government initiatives and funding for epigenetics research 72
- 5.2.1.4 Technological advancements in epigenetics research 72
- 5.2.1.5 Rising demand for epigenetic-based therapeutics 73
5.2.2 RESTRAINTS 74
- 5.2.2.1 Limited applications of epigenomic data in toxicology 74
- 5.2.2.2 Data privacy concerns and security issues 75
5.2.3 OPPORTUNITIES 75
- 5.2.3.1 Expanding applications of epigenetics 75
- 5.2.3.2 Integration of artificial intelligence and machine learning algorithms 76
5.2.4 CHALLENGES 76
- 5.2.4.1 Concerns regarding quality of antibodies 76
- 5.2.4.2 Challenges associated with epigenetic editing 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.4 PRICING ANALYSIS 78
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 78
5.4.2 AVERAGE SELLING PRICE TREND 79
5.5 TECHNOLOGY ANALYSIS 79
5.6 VALUE CHAIN ANALYSIS 80
5.7 ECOSYSTEM MAP 81
5.8 REGULATORY ANALYSIS 83
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
5.9 PORTER’S FIVE FORCES ANALYSIS 88
5.9.1 THREAT OF NEW ENTRANTS 88
5.9.2 THREAT OF SUBSTITUTES 89
5.9.3 BARGAINING POWER OF SUPPLIERS 89
5.9.4 BARGAINING POWER OF BUYERS 89
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 89
5.10 PATENT ANALYSIS 90
5.11 KEY CONFERENCES & EVENTS 91
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
5.12.2 BUYING CRITERIA FOR EPIGENETICS 93
6 EPIGENETICS MARKET, BY PRODUCT & SERVICE 94
6.1 INTRODUCTION 95
6.2 KITS & REAGENTS 95
6.2.1 ANTIBODIES 98
- 6.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel growth 98
6.2.2 CHIP-SEQUENCING KITS & REAGENTS 101
- 6.2.2.1 Versatile applications of chromatin immunoprecipitation (ChIP) pertaining to epigenetic regulatory systems to boost demand 101
6.2.3 BISULFITE CONVERSION KITS & REAGENTS 104
- 6.2.3.1 Effective outcomes associated with bisulfite conversion to drive demand 104
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 107
- 6.2.4.1 Ability of whole-genome amplification to maintain relative proportions of genes in original pool to drive adoption 107
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 110
- 6.2.5.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 110
6.2.6 HISTONES 113
- 6.2.6.1 Emerging importance of chromatin-associated proteins and histones in epigenetic research to drive segmental growth 113
6.2.7 OTHER KITS & REAGENTS 116
6.3 ENZYMES 119
6.3.1 DNA-MODIFYING ENZYMES 121
- 6.3.1.1 Broadening applications of DNA methylation to favor market growth 121
6.3.2 PROTEIN-MODIFYING ENZYMES 124
- 6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive segmental growth 124
6.3.3 OTHER ENZYMES 127
6.4 INSTRUMENTS & ACCESSORIES 129
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO PROPEL GROWTH 129
6.5 SOFTWARE 132
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROPEL GROWTH 132
6.6 SERVICES 135
6.6.1 EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE GROWTH 135
7 EPIGENETICS MARKET, BY METHOD 139
7.1 INTRODUCTION 140
7.2 DNA METHYLATION 140
7.2.1 INCREASING R&D ACTIVITIES TO EXPLORE POTENTIAL OF DNA METHYLATION TO DRIVE MARKET GROWTH 140
7.3 HISTONE MODIFICATIONS 143
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENTAL GROWTH 143
7.4 OTHER METHODS 146
8 EPIGENETICS MARKET, BY TECHNIQUE 150
8.1 INTRODUCTION 151
8.2 NGS 151
8.2.1 ABILITY TO OFFER COMPREHENSIVE EPIGENETIC PROFILES TO PROPEL DEMAND FOR NGS TECHNIQUE 151
8.3 PCR & QPCR 154
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE GROWTH 154
8.4 MASS SPECTROMETRY 157
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 157
8.5 SONICATION 160
8.5.1 INTRODUCTION OF IMPROVED HIGH-THROUGHPUT SONICATION TECHNIQUES TO PROPEL ADOPTION 160
8.6 OTHER TECHNIQUES 163
9 EPIGENETICS MARKET, BY APPLICATION 167
9.1 INTRODUCTION 168
9.2 ONCOLOGY 168
9.2.1 GROWING EFFORTS TO DEVELOP ONCOLOGY EPIGENETIC DRUGS TO BOOST MARKET 168
9.3 METABOLIC DISEASES 173
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR MARKET GROWTH 173
9.4 IMMUNOLOGY 176
9.4.1 GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO SUPPORT GROWTH 176
9.5 DEVELOPMENTAL BIOLOGY 179
9.5.1 INCREASING RESEARCH IN DEVELOPMENTAL BIOLOGY TO PROPEL GROWTH 179
9.6 CARDIOVASCULAR DISEASES 182
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO BOOST ADOPTION 182
9.7 OTHER APPLICATIONS 185
10 EPIGENETICS MARKET, BY END USER 189
10.1 INTRODUCTION 190
10.2 ACADEMIC & RESEARCH INSTITUTES 190
10.2.1 INCREASING GOVERNMENT INVESTMENTS & COLLABORATIONS TO CONTRIBUTE TO MARKET GROWTH 190
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 193
10.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE GROWTH 193
10.4 HOSPITALS & CLINICS 196
10.4.1 GROWING IMPORTANCE OF MEASUREMENT OF DNA METHYLATION IN HOSPITAL SETTINGS TO BOOST MARKET 196
11 EPIGENETICS MARKET, BY REGION 200
11.1 INTRODUCTION 201
11.2 NORTH AMERICA 201
11.2.1 US 205
- 11.2.1.1 Strong network of well-established epigenetic product manufacturers to drive market growth 205
11.2.2 CANADA 209
- 11.2.2.1 Increasing government initiatives to boost epigenetics research 209
11.3 NORTH AMERICA: RECESSION IMPACT 213
11.4 EUROPE 214
11.4.1 GERMANY 217
- 11.4.1.1 Significant investments in NGS to boost adoption of epigenetics products 217
11.4.2 UK 221
- 11.4.2.1 Rising acceptance of genome-based diagnostic techniques by clinicians to support growth 221
11.4.3 FRANCE 224
- 11.4.3.1 Growing demand for PCR technologies to propel market growth 224
11.4.4 ITALY 227
- 11.4.4.1 High incidence of cancer to support market growth 227
11.4.5 SPAIN 230
- 11.4.5.1 Well-established network of research centers and universities to boost market 230
11.4.6 REST OF EUROPE 233
11.5 EUROPE: RECESSION IMPACT 236
11.6 ASIA PACIFIC 237
11.6.1 JAPAN 242
- 11.6.1.1 Increasing collaborations between research & academic organizations to favor market growth 242
11.6.2 CHINA 246
- 11.6.2.1 High demand for personalized medicine to fuel growth 246
11.6.3 INDIA 250
- 11.6.3.1 Expanding base of biotechnology facilities to drive growth 250
11.6.4 SOUTH KOREA 254
- 11.6.4.1 Increasing demand for epigenetic testing to boost growth 254
11.6.5 REST OF ASIA PACIFIC 257
11.6.6 ASIA PACIFIC: RECESSION IMPACT 260
11.7 LATIN AMERICA 261
11.7.1 BRAZIL 264
- 11.7.1.1 Increasing number of healthcare providers incorporating epigenetic testing to boost growth 264
11.7.2 MEXICO 267
- 11.7.2.1 Growing adoption of cutting-edge technologies to support growth 267
11.7.3 REST OF LATIN AMERICA 270
11.7.4 LATIN AMERICA: RECESSION IMPACT 273
11.8 MIDDLE EAST 274
11.8.1 INCREASE IN FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO BOOST GROWTH 274
11.8.2 MIDDLE EAST: RECESSION IMPACT 277
11.9 AFRICA 278
11.9.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 278
11.9.2 AFRICA: RECESSION IMPACT 281
12 COMPETITIVE LANDSCAPE 282
12.1 INTRODUCTION 282
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 283
12.3 REVENUE ANALYSIS 284
12.4 MARKET SHARE ANALYSIS 284
12.5 COMPANY EVALUATION MATRIX 286
12.5.1 STARS 286
12.5.2 EMERGING LEADERS 287
12.5.3 PERVASIVE PLAYERS 287
12.5.4 PARTICIPANTS 287
12.5.5 COMPANY FOOTPRINT ANALYSIS 289
12.6 START-UP/SME EVALUATION QUADRANT 291
12.6.1 PROGRESSIVE COMPANIES 291
12.6.2 RESPONSIVE COMPANIES 291
12.6.3 DYNAMIC COMPANIES 291
12.6.4 STARTING BLOCKS 291
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 293
12.7 COMPETITIVE SCENARIO & TRENDS 294
12.7.1 PRODUCT LAUNCHES & APPROVALS 294
12.7.2 DEALS 295
12.7.3 OTHER DEVELOPMENTS 296
13 COMPANY PROFILES 297
13.1 KEY MARKET PLAYERS 297
13.1.1 THERMO FISHER SCIENTIFIC INC 297
13.1.2 ILLUMINA, INC 301
13.1.3 MERCK KGAA 305
13.1.4 PACBIO 309
13.1.5 ABCAM PLC 313
13.1.6 BIO-RAD LABORATORIES, INC 317
13.1.7 ACTIVE MOTIF INC 322
13.1.8 NEW ENGLAND BIOLABS 326
13.1.9 QIAGEN 329
13.1.10 ZYMO RESEARCH CORPORATION 332
13.1.11 REVVITY 335
13.1.12 DIAGENODE SA (A HOLOGIC COMPANY) 338
13.1.13 F. HOFFMANN-LA ROCHE LTD 341
13.1.14 PROMEGA CORPORATION 343
13.1.15 EPIGENTEK GROUP INC 345
13.2 OTHER PLAYERS 349
13.2.1 EPICYPHER 349
13.2.2 FIOS GENOMICS 350
13.2.3 GENOMESCAN 351
13.2.4 CREATIVE BIOGENE 352
13.2.5 BPS BIOSCIENCE, INC 353
13.2.6 ABNOVA CORPORATION 354
13.2.7 CREATIVE DIAGNOSTICS 355
13.2.8 BIOMODAL (FORMERLY CAMBRIDGE EPIGENETIX) 356
13.2.9 INTEGRATED DNA TECHNOLOGIES, INC 356
13.2.10 NOVOGENE CO., LTD 358
14 APPENDIX 359
14.1 DISCUSSION GUIDE 359
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363
14.3 CUSTOMIZATION OPTIONS 365
14.4 RELATED REPORTS 365
14.5 AUTHOR DETAILS 366